The clinical spectrum of Castleman's disease
Castleman's disease (CD) is a rare, poorly understood lymphoproliferative disease. The spectrum of symptoms and course of disease are broad, but there is no large study describing the natural history of this disease. Basic clinic and laboratory data from the records of 113 patients with CD eval...
Gespeichert in:
| Veröffentlicht in: | American journal of hematology 2012-11, Vol.87 (11), p.997-1002 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1002 |
|---|---|
| container_issue | 11 |
| container_start_page | 997 |
| container_title | American journal of hematology |
| container_volume | 87 |
| creator | Dispenzieri, Angela Armitage, James O. Loe, Matt J. Geyer, Susan M. Allred, Jake Camoriano, John K. Menke, David M. Weisenburger, Dennis D. Ristow, Kay Dogan, Ahmet Habermann, Thomas M. |
| description | Castleman's disease (CD) is a rare, poorly understood lymphoproliferative disease. The spectrum of symptoms and course of disease are broad, but there is no large study describing the natural history of this disease. Basic clinic and laboratory data from the records of 113 patients with CD evaluated at the Mayo Clinic and University of Nebraska were ed. The impact of these variables on overall survival (OS) from time of diagnosis was evaluated. Sixty patients had multicentric disease. Of the patients with multicentric CD, 32% had criteria sufficient for a diagnosis of POEMS syndrome. For all patients, 2, 5, and 10‐year OS was 92%, 76%, 59%, respectively. Most of the factors identified as risk factors for death on univariate analysis cosegregated with diagnostic criteria for POEMS syndrome, which supported the concept of four categories of CD, which are (along with their 5‐year OS): (1) unicentric CD (91%); (2) multicentric CD associated with the osteosclerotic variant of POEMS syndrome (90%); (3); multicentric CD without POEMS syndrome (65%); and (4) multicentric CD with POEMS syndrome without osteosclerotic lesions (27%). We have demonstrated that CD represents a spectrum of disease that can be differentiated by simple prognostic factors that provide a framework for further study. Am. J. Hematol. 2012. © 2012 Wiley Periodicals, Inc. |
| doi_str_mv | 10.1002/ajh.23291 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3900496</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1114949784</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5771-ea63b50a2bb068598cbede1856dc58698b812f6c4a5e48ef1540f2c0066f95303</originalsourceid><addsrcrecordid>eNp1kd1rFDEUxYModlt98B-QAREVnPYmmXy9CO1iW6UoQtXHkMnecbPOx5rMqP3vTbvb9QN8SiC_e87NOYQ8onBIAdiRWy0PGWeG3iEzCkaWWgp2l8yAS5rvYPbIfkorAEorDffJHmPK0IqqGXl5ucTCt6EP3rVFWqMf49QVQ1PMXRpb7Fz_LBWLkNAlfEDuNa5N-HB7HpCPp68v5-flxfuzN_Pji9ILpWiJTvJagGN1DVILo32NC6RayIUXWhpda8oa6SsnsNLYUFFBwzyAlI0RHPgBebXRXU91hwuP_Rhda9cxdC5e2cEF-_dLH5b2y_DdcgNQGZkFnm8F4vBtwjTaLiSPbet6HKZkaQ7CVEbpKqNP_kFXwxT7_L0biikhOc_Uiw3l45BSxGa3DAV73YHNHdibDjL7-M_td-Rt6Bl4ugVcyqk30fU-pN-cFDIbX8dwtOF-hBav_u9oj9-e31qXm4mQRvy5m3Dxq5WKK2E_vzuzJ59OleYfhDX8F6phqkk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1114275633</pqid></control><display><type>article</type><title>The clinical spectrum of Castleman's disease</title><source>MEDLINE</source><source>Wiley Online Library</source><source>Wiley Online Library Free Content</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Dispenzieri, Angela ; Armitage, James O. ; Loe, Matt J. ; Geyer, Susan M. ; Allred, Jake ; Camoriano, John K. ; Menke, David M. ; Weisenburger, Dennis D. ; Ristow, Kay ; Dogan, Ahmet ; Habermann, Thomas M.</creator><creatorcontrib>Dispenzieri, Angela ; Armitage, James O. ; Loe, Matt J. ; Geyer, Susan M. ; Allred, Jake ; Camoriano, John K. ; Menke, David M. ; Weisenburger, Dennis D. ; Ristow, Kay ; Dogan, Ahmet ; Habermann, Thomas M.</creatorcontrib><description>Castleman's disease (CD) is a rare, poorly understood lymphoproliferative disease. The spectrum of symptoms and course of disease are broad, but there is no large study describing the natural history of this disease. Basic clinic and laboratory data from the records of 113 patients with CD evaluated at the Mayo Clinic and University of Nebraska were ed. The impact of these variables on overall survival (OS) from time of diagnosis was evaluated. Sixty patients had multicentric disease. Of the patients with multicentric CD, 32% had criteria sufficient for a diagnosis of POEMS syndrome. For all patients, 2, 5, and 10‐year OS was 92%, 76%, 59%, respectively. Most of the factors identified as risk factors for death on univariate analysis cosegregated with diagnostic criteria for POEMS syndrome, which supported the concept of four categories of CD, which are (along with their 5‐year OS): (1) unicentric CD (91%); (2) multicentric CD associated with the osteosclerotic variant of POEMS syndrome (90%); (3); multicentric CD without POEMS syndrome (65%); and (4) multicentric CD with POEMS syndrome without osteosclerotic lesions (27%). We have demonstrated that CD represents a spectrum of disease that can be differentiated by simple prognostic factors that provide a framework for further study. Am. J. Hematol. 2012. © 2012 Wiley Periodicals, Inc.</description><identifier>ISSN: 0361-8609</identifier><identifier>EISSN: 1096-8652</identifier><identifier>DOI: 10.1002/ajh.23291</identifier><identifier>PMID: 22791417</identifier><identifier>CODEN: AJHEDD</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adolescent ; Adult ; Aged ; Biological and medical sciences ; Biopsy, Needle ; Castleman Disease - complications ; Castleman Disease - diagnosis ; Castleman Disease - mortality ; Castleman Disease - therapy ; Child ; Child, Preschool ; Data Interpretation, Statistical ; Disease-Free Survival ; Female ; Hematologic and hematopoietic diseases ; Hematology ; Humans ; Kaplan-Meier Estimate ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Lymph Nodes - pathology ; Male ; Medical sciences ; Middle Aged ; Other diseases. Hematologic involvement in other diseases ; POEMS Syndrome - complications ; POEMS Syndrome - diagnosis ; POEMS Syndrome - mortality ; POEMS Syndrome - therapy ; Proportional Hazards Models ; Retrospective Studies ; Treatment Outcome ; Young Adult</subject><ispartof>American journal of hematology, 2012-11, Vol.87 (11), p.997-1002</ispartof><rights>Copyright © 2012 Wiley Periodicals, Inc.</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5771-ea63b50a2bb068598cbede1856dc58698b812f6c4a5e48ef1540f2c0066f95303</citedby><cites>FETCH-LOGICAL-c5771-ea63b50a2bb068598cbede1856dc58698b812f6c4a5e48ef1540f2c0066f95303</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fajh.23291$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fajh.23291$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26561420$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22791417$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dispenzieri, Angela</creatorcontrib><creatorcontrib>Armitage, James O.</creatorcontrib><creatorcontrib>Loe, Matt J.</creatorcontrib><creatorcontrib>Geyer, Susan M.</creatorcontrib><creatorcontrib>Allred, Jake</creatorcontrib><creatorcontrib>Camoriano, John K.</creatorcontrib><creatorcontrib>Menke, David M.</creatorcontrib><creatorcontrib>Weisenburger, Dennis D.</creatorcontrib><creatorcontrib>Ristow, Kay</creatorcontrib><creatorcontrib>Dogan, Ahmet</creatorcontrib><creatorcontrib>Habermann, Thomas M.</creatorcontrib><title>The clinical spectrum of Castleman's disease</title><title>American journal of hematology</title><addtitle>Am. J. Hematol</addtitle><description>Castleman's disease (CD) is a rare, poorly understood lymphoproliferative disease. The spectrum of symptoms and course of disease are broad, but there is no large study describing the natural history of this disease. Basic clinic and laboratory data from the records of 113 patients with CD evaluated at the Mayo Clinic and University of Nebraska were ed. The impact of these variables on overall survival (OS) from time of diagnosis was evaluated. Sixty patients had multicentric disease. Of the patients with multicentric CD, 32% had criteria sufficient for a diagnosis of POEMS syndrome. For all patients, 2, 5, and 10‐year OS was 92%, 76%, 59%, respectively. Most of the factors identified as risk factors for death on univariate analysis cosegregated with diagnostic criteria for POEMS syndrome, which supported the concept of four categories of CD, which are (along with their 5‐year OS): (1) unicentric CD (91%); (2) multicentric CD associated with the osteosclerotic variant of POEMS syndrome (90%); (3); multicentric CD without POEMS syndrome (65%); and (4) multicentric CD with POEMS syndrome without osteosclerotic lesions (27%). We have demonstrated that CD represents a spectrum of disease that can be differentiated by simple prognostic factors that provide a framework for further study. Am. J. Hematol. 2012. © 2012 Wiley Periodicals, Inc.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Biopsy, Needle</subject><subject>Castleman Disease - complications</subject><subject>Castleman Disease - diagnosis</subject><subject>Castleman Disease - mortality</subject><subject>Castleman Disease - therapy</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Data Interpretation, Statistical</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematology</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Lymph Nodes - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Other diseases. Hematologic involvement in other diseases</subject><subject>POEMS Syndrome - complications</subject><subject>POEMS Syndrome - diagnosis</subject><subject>POEMS Syndrome - mortality</subject><subject>POEMS Syndrome - therapy</subject><subject>Proportional Hazards Models</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0361-8609</issn><issn>1096-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kd1rFDEUxYModlt98B-QAREVnPYmmXy9CO1iW6UoQtXHkMnecbPOx5rMqP3vTbvb9QN8SiC_e87NOYQ8onBIAdiRWy0PGWeG3iEzCkaWWgp2l8yAS5rvYPbIfkorAEorDffJHmPK0IqqGXl5ucTCt6EP3rVFWqMf49QVQ1PMXRpb7Fz_LBWLkNAlfEDuNa5N-HB7HpCPp68v5-flxfuzN_Pji9ILpWiJTvJagGN1DVILo32NC6RayIUXWhpda8oa6SsnsNLYUFFBwzyAlI0RHPgBebXRXU91hwuP_Rhda9cxdC5e2cEF-_dLH5b2y_DdcgNQGZkFnm8F4vBtwjTaLiSPbet6HKZkaQ7CVEbpKqNP_kFXwxT7_L0biikhOc_Uiw3l45BSxGa3DAV73YHNHdibDjL7-M_td-Rt6Bl4ugVcyqk30fU-pN-cFDIbX8dwtOF-hBav_u9oj9-e31qXm4mQRvy5m3Dxq5WKK2E_vzuzJ59OleYfhDX8F6phqkk</recordid><startdate>201211</startdate><enddate>201211</enddate><creator>Dispenzieri, Angela</creator><creator>Armitage, James O.</creator><creator>Loe, Matt J.</creator><creator>Geyer, Susan M.</creator><creator>Allred, Jake</creator><creator>Camoriano, John K.</creator><creator>Menke, David M.</creator><creator>Weisenburger, Dennis D.</creator><creator>Ristow, Kay</creator><creator>Dogan, Ahmet</creator><creator>Habermann, Thomas M.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201211</creationdate><title>The clinical spectrum of Castleman's disease</title><author>Dispenzieri, Angela ; Armitage, James O. ; Loe, Matt J. ; Geyer, Susan M. ; Allred, Jake ; Camoriano, John K. ; Menke, David M. ; Weisenburger, Dennis D. ; Ristow, Kay ; Dogan, Ahmet ; Habermann, Thomas M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5771-ea63b50a2bb068598cbede1856dc58698b812f6c4a5e48ef1540f2c0066f95303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Biopsy, Needle</topic><topic>Castleman Disease - complications</topic><topic>Castleman Disease - diagnosis</topic><topic>Castleman Disease - mortality</topic><topic>Castleman Disease - therapy</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Data Interpretation, Statistical</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematology</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Lymph Nodes - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Other diseases. Hematologic involvement in other diseases</topic><topic>POEMS Syndrome - complications</topic><topic>POEMS Syndrome - diagnosis</topic><topic>POEMS Syndrome - mortality</topic><topic>POEMS Syndrome - therapy</topic><topic>Proportional Hazards Models</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dispenzieri, Angela</creatorcontrib><creatorcontrib>Armitage, James O.</creatorcontrib><creatorcontrib>Loe, Matt J.</creatorcontrib><creatorcontrib>Geyer, Susan M.</creatorcontrib><creatorcontrib>Allred, Jake</creatorcontrib><creatorcontrib>Camoriano, John K.</creatorcontrib><creatorcontrib>Menke, David M.</creatorcontrib><creatorcontrib>Weisenburger, Dennis D.</creatorcontrib><creatorcontrib>Ristow, Kay</creatorcontrib><creatorcontrib>Dogan, Ahmet</creatorcontrib><creatorcontrib>Habermann, Thomas M.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>American journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dispenzieri, Angela</au><au>Armitage, James O.</au><au>Loe, Matt J.</au><au>Geyer, Susan M.</au><au>Allred, Jake</au><au>Camoriano, John K.</au><au>Menke, David M.</au><au>Weisenburger, Dennis D.</au><au>Ristow, Kay</au><au>Dogan, Ahmet</au><au>Habermann, Thomas M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The clinical spectrum of Castleman's disease</atitle><jtitle>American journal of hematology</jtitle><addtitle>Am. J. Hematol</addtitle><date>2012-11</date><risdate>2012</risdate><volume>87</volume><issue>11</issue><spage>997</spage><epage>1002</epage><pages>997-1002</pages><issn>0361-8609</issn><eissn>1096-8652</eissn><coden>AJHEDD</coden><abstract>Castleman's disease (CD) is a rare, poorly understood lymphoproliferative disease. The spectrum of symptoms and course of disease are broad, but there is no large study describing the natural history of this disease. Basic clinic and laboratory data from the records of 113 patients with CD evaluated at the Mayo Clinic and University of Nebraska were ed. The impact of these variables on overall survival (OS) from time of diagnosis was evaluated. Sixty patients had multicentric disease. Of the patients with multicentric CD, 32% had criteria sufficient for a diagnosis of POEMS syndrome. For all patients, 2, 5, and 10‐year OS was 92%, 76%, 59%, respectively. Most of the factors identified as risk factors for death on univariate analysis cosegregated with diagnostic criteria for POEMS syndrome, which supported the concept of four categories of CD, which are (along with their 5‐year OS): (1) unicentric CD (91%); (2) multicentric CD associated with the osteosclerotic variant of POEMS syndrome (90%); (3); multicentric CD without POEMS syndrome (65%); and (4) multicentric CD with POEMS syndrome without osteosclerotic lesions (27%). We have demonstrated that CD represents a spectrum of disease that can be differentiated by simple prognostic factors that provide a framework for further study. Am. J. Hematol. 2012. © 2012 Wiley Periodicals, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>22791417</pmid><doi>10.1002/ajh.23291</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0361-8609 |
| ispartof | American journal of hematology, 2012-11, Vol.87 (11), p.997-1002 |
| issn | 0361-8609 1096-8652 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3900496 |
| source | MEDLINE; Wiley Online Library; Wiley Online Library Free Content; EZB-FREE-00999 freely available EZB journals |
| subjects | Adolescent Adult Aged Biological and medical sciences Biopsy, Needle Castleman Disease - complications Castleman Disease - diagnosis Castleman Disease - mortality Castleman Disease - therapy Child Child, Preschool Data Interpretation, Statistical Disease-Free Survival Female Hematologic and hematopoietic diseases Hematology Humans Kaplan-Meier Estimate Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymph Nodes - pathology Male Medical sciences Middle Aged Other diseases. Hematologic involvement in other diseases POEMS Syndrome - complications POEMS Syndrome - diagnosis POEMS Syndrome - mortality POEMS Syndrome - therapy Proportional Hazards Models Retrospective Studies Treatment Outcome Young Adult |
| title | The clinical spectrum of Castleman's disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T09%3A50%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20clinical%20spectrum%20of%20Castleman's%20disease&rft.jtitle=American%20journal%20of%20hematology&rft.au=Dispenzieri,%20Angela&rft.date=2012-11&rft.volume=87&rft.issue=11&rft.spage=997&rft.epage=1002&rft.pages=997-1002&rft.issn=0361-8609&rft.eissn=1096-8652&rft.coden=AJHEDD&rft_id=info:doi/10.1002/ajh.23291&rft_dat=%3Cproquest_pubme%3E1114949784%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1114275633&rft_id=info:pmid/22791417&rfr_iscdi=true |